What is Survodutide?
Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) and receptor (GLP-1R) agonist designed for once-weekly subcutaneous administration. This 29-amino acid peptide with C18 fatty acid acylation represents a novel approach to metabolic disease treatment by simultaneously targeting both energy intake reduction (via GLP-1R) and energy expenditure increase (via GCGR), demonstrating robust efficacy in clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH).